{"protocolSection": {"identificationModule": {"nctId": "NCT01059175", "orgStudyIdInfo": {"id": "Medtronic"}, "organization": {"fullName": "Medtronic Bakken Research Center", "class": "INDUSTRY"}, "briefTitle": "Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial", "officialTitle": "Dual-Site LV Pacing in CRT Non Responders Multicenter Randomized V3 Trial", "acronym": "V3"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-09"}, "primaryCompletionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-01-26", "studyFirstSubmitQcDate": "2010-01-28", "studyFirstPostDateStruct": {"date": "2010-01-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-05-25", "resultsFirstSubmitQcDate": "2017-04-18", "resultsFirstPostDateStruct": {"date": "2017-04-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-18", "lastUpdatePostDateStruct": {"date": "2017-04-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Medtronic Bakken Research Center", "class": "INDUSTRY"}, "collaborators": [{"name": "Medtronic", "class": "INDUSTRY"}, {"name": "FRANCE", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Cardiac resynchronization therapy (CRT) is an effective treatment of heart failure (HF) refractory to optimal medical management, in presence of a depressed left ventricular (LV) ejection fraction and a wide QRS complex. It is mainly limited by a high proportion of non-responders. Attempts have been made, in small studies, to increase the number of stimulation sites in order to optimize the resynchronization therapy. V3 is a planned multicenter, randomized trial whose objective is to evaluate the clinical benefit conferred by the addition of a second endocardial or epicardial LV lead in non-responders after at least 6 months of standard biventricular stimulation.\n\nThe V3 trial will examine the clinical benefit conferred by the addition of a second LV lead in non-responders compared to standard CRT."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart failure", "Cardiac resynchronization therapy", "Biventricular stimulation", "Multisite stimulation", "Non responders"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 84, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "CRT With Dual Site LV Pacing", "type": "EXPERIMENTAL", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.", "interventionNames": ["Device: Additional Endocardial or Epicardial LV Lead", "Device: CRT-P or CRT-D"]}, {"label": "Standard CRT", "type": "ACTIVE_COMPARATOR", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.", "interventionNames": ["Device: CRT-P or CRT-D"]}], "interventions": [{"type": "DEVICE", "name": "Additional Endocardial or Epicardial LV Lead", "description": "Addition of a second left ventricular endocardial or epicardial lead", "armGroupLabels": ["CRT With Dual Site LV Pacing"]}, {"type": "DEVICE", "name": "CRT-P or CRT-D", "description": "Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device", "armGroupLabels": ["CRT With Dual Site LV Pacing", "Standard CRT"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Distribution of \"Improved\", \"Unchanged\" and \"Worsened\" Patients as Defined Per M. Packer's Clinical Composite Score", "description": "M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 12 months follow up : worsened, unchanged, or improved.\n\nWorsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 12-month visit, or if investigator judges global clinical state has worsened.\n\nImproved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.\n\nUnchanged : if none of the previous definition applies.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Distribution of \"Improved\", \"Unchanged\" and \"Worsened\" Patients as Defined Per M. Packer's Clinical Composite Score", "description": "Distribution of \"improved\", \"unchanged\" and \"worsened\" patients as defined per M. Packer's clinical composite score at 24 months post implantation of the second left ventricle lead in comparison to the control group M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 24 months follow up : worsened, unchanged, or improved.\n\nWorsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 24-month visit, or if investigator judges global clinical state has worsened.\n\nImproved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.\n\nUnchanged : if none of the previous definition applies.", "timeFrame": "24 months"}, {"measure": "Rate of Adverse Events", "timeFrame": "24 months"}, {"measure": "Changes in 6 Minutes Hall Walk Distance Observed Between the Enrollment and the End of the Study", "description": "Changes between baseline and 24months follow up", "timeFrame": "24 months"}, {"measure": "Number of Patients With at Least One Hospitalization Related to Heart Failure Between Randomization and the End of the Study", "timeFrame": "24 months"}, {"measure": "Time to First Heart Failure Related Hospitalization", "timeFrame": "24 months"}, {"measure": "Overall Mortality", "timeFrame": "24 months"}, {"measure": "Changes in Echocardiographic Indexes of Left Ventricle Remodeling", "description": "Changes between baseline and 24months follow up", "timeFrame": "24 months"}, {"measure": "Changes in Quality of Life Score - Minesota Living With Heart Failure Questionnaire", "description": "Changes between baseline and 24 months follow up Minesota Living with Heart Failure Questionnaire: 21 questions - addition of scores from 1 (better) to 5 (worse) for each questions.", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age greater than 18 years\n* Recipient of a CRT-P or CRT-D system for greater than 6 for standard indications, including LV ejection fraction greater than 35 percent and New York Heart Association (NYHA) functional class III or IV\n* Optimized biventricular stimulation and medical therapy since implantation of the system\n* Presence of sinus rhythm, or atrial fibrillation with spontaneous or induced complete atrio-ventricular block\n* Greater than 93 percent LV stimulation since the last device interrogation, with a LV capture threshold less than 5.0 Volts/0.5 milliseconds\n* Unchanged or worsened clinical status by CRT, according to the HF composite endpoint described by M. Packer, in absence of a reversible cause\n* Signature of a written, informed consent to participate in the trial\n\nExclusion Criteria:\n\n* LV lead location in the great cardiac vein\n* Life-expectancy less than 1 year due to concomitant, non-cardiovascular disorders\n* Chronic renal dialysis\n* Concomitant disorder which might interfere with the results of the V3 trial\n* Blood systolic pressure greater than 180 millimeters of mercury (mmHg) or diastolic pressure greater than 95 mmHg despite optimal medical management\n* History of stroke, myocardial infarction or unstable angina pectoris within the last 3 months\n* Presence of correctible valvular disease\n* Subject unable to attend follow-up at the investigative center or unable, for physical or mental reasons, to comply with the trial's procedures, or to sign the informed consent\n* Subject is pregnant\n* Subject participates in another research project", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bordachar, MD", "affiliation": "University Hospital, Bordeaux", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University hospital Rennes", "city": "Rennes", "zip": "35000", "country": "France", "geoPoint": {"lat": 48.11198, "lon": -1.67429}}]}, "referencesModule": {"references": [{"pmid": "20797593", "type": "BACKGROUND", "citation": "Bordachar P, Alonso C, Anselme F, Boveda S, Defaye P, Garrigue S, Gras D, Klug D, Piot O, Sadoul N, Leclercq C. Addition of a second LV pacing site in CRT nonresponders rationale and design of the multicenter randomized V(3) trial. J Card Fail. 2010 Sep;16(9):709-13. doi: 10.1016/j.cardfail.2010.04.010. Epub 2010 Jun 8."}, {"pmid": "29288035", "type": "DERIVED", "citation": "Bordachar P, Gras D, Clementy N, Defaye P, Mondoly P, Boveda S, Anselme F, Klug D, Piot O, Sadoul N, Babuty D, Leclercq C. Clinical impact of an additional left ventricular lead in cardiac resynchronization therapy nonresponders: The V3 trial. Heart Rhythm. 2018 Jun;15(6):870-876. doi: 10.1016/j.hrthm.2017.12.028. Epub 2017 Dec 26."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "FG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "43"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "17 patients deceased 4 additional patients were prematurely exited", "numSubjects": "22"}, {"groupId": "FG001", "comment": "17 patients deceased 3 patients were prematurely exited", "numSubjects": "21"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "One patient of the V3 group was not included in the ITT analysis of efficacy results as he did not meet inclusion criteria so 83 pts were analyzed", "groups": [{"id": "BG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "BG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "83"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.5", "spread": "7.7"}, {"groupId": "BG001", "value": "72.2", "spread": "7.9"}, {"groupId": "BG002", "value": "71.3", "spread": "7.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "72"}]}]}]}, {"title": "Patients with ischemic heart disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Paced QRS duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milliseconds", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "165", "spread": "30.5"}, {"groupId": "BG001", "value": "155", "spread": "42.2"}, {"groupId": "BG002", "value": "160", "spread": "36.8"}]}]}]}, {"title": "Time from first CRT implant", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.5", "spread": "28.4"}, {"groupId": "BG001", "value": "37.8", "spread": "23.7"}, {"groupId": "BG002", "value": "40.6", "spread": "26.2"}]}]}]}, {"title": "LVEF % (left ventricle ejection fraction)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.9", "spread": "6.0"}, {"groupId": "BG001", "value": "25.9", "spread": "7.0"}, {"groupId": "BG002", "value": "26.4", "spread": "6.4"}]}]}]}, {"title": "LVEDV (left ventricular end-diastolic volume)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milliliter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "219", "spread": "85.8"}, {"groupId": "BG001", "value": "206", "spread": "63.9"}, {"groupId": "BG002", "value": "213", "spread": "75.7"}]}]}]}, {"title": "LVESV (left ventricular end-systolic volume)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milliliter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "154", "spread": "61.8"}, {"groupId": "BG001", "value": "149", "spread": "58.7"}, {"groupId": "BG002", "value": "151", "spread": "59.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Distribution of \"Improved\", \"Unchanged\" and \"Worsened\" Patients as Defined Per M. Packer's Clinical Composite Score", "description": "M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 12 months follow up : worsened, unchanged, or improved.\n\nWorsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 12-month visit, or if investigator judges global clinical state has worsened.\n\nImproved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.\n\nUnchanged : if none of the previous definition applies.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"title": "Improved patients", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Unchanged patients", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Worsened patients", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "17"}]}]}]}, {"type": "SECONDARY", "title": "Distribution of \"Improved\", \"Unchanged\" and \"Worsened\" Patients as Defined Per M. Packer's Clinical Composite Score", "description": "Distribution of \"improved\", \"unchanged\" and \"worsened\" patients as defined per M. Packer's clinical composite score at 24 months post implantation of the second left ventricle lead in comparison to the control group M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 24 months follow up : worsened, unchanged, or improved.\n\nWorsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 24-month visit, or if investigator judges global clinical state has worsened.\n\nImproved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.\n\nUnchanged : if none of the previous definition applies.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"title": "Patients improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Patients unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "Patients worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "25"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Adverse Events", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"title": "Patients with at least one AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "34"}]}]}, {"title": "Patients with at least one severe AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "33"}]}]}]}, {"type": "SECONDARY", "title": "Changes in 6 Minutes Hall Walk Distance Observed Between the Enrollment and the End of the Study", "description": "Changes between baseline and 24months follow up", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.1", "spread": "88.0"}, {"groupId": "OG001", "value": "7.5", "spread": "96.3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With at Least One Hospitalization Related to Heart Failure Between Randomization and the End of the Study", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "22"}]}]}]}, {"type": "SECONDARY", "title": "Time to First Heart Failure Related Hospitalization", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "days", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "357.6", "spread": "27.17"}, {"groupId": "OG001", "value": "402.4", "spread": "41.16"}]}]}]}, {"type": "SECONDARY", "title": "Overall Mortality", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Echocardiographic Indexes of Left Ventricle Remodeling", "description": "Changes between baseline and 24months follow up", "populationDescription": "Number of patients with data available for analysis of this objective", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "milliliter", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"title": "Changes in LVEDV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.4", "spread": "78.6"}, {"groupId": "OG001", "value": "7.0", "spread": "72.1"}]}]}, {"title": "Changes in LVESV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.3", "spread": "57.6"}, {"groupId": "OG001", "value": "-2.0", "spread": "60.6"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Quality of Life Score - Minesota Living With Heart Failure Questionnaire", "description": "Changes between baseline and 24 months follow up Minesota Living with Heart Failure Questionnaire: 21 questions - addition of scores from 1 (better) to 5 (worse) for each questions.", "populationDescription": "Number of patients with data available for analysis of this objective", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}, {"id": "OG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.33", "spread": "23.5"}, {"groupId": "OG001", "value": "-7.48", "spread": "17.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "CRT With Dual Site LV Pacing", "description": "Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.\n\nAdditional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device", "seriousNumAffected": 33, "seriousNumAtRisk": 42, "otherNumAffected": 38, "otherNumAtRisk": 42}, {"id": "EG001", "title": "Standard CRT", "description": "Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.\n\nCRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device", "seriousNumAffected": 33, "seriousNumAtRisk": 41, "otherNumAffected": 34, "otherNumAtRisk": 41}], "seriousEvents": [{"term": "Severe cardiovascular event", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Definition as per ISO 14155", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 42}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 41}]}], "otherEvents": [{"term": "Cardiac AE", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Definition as per ISO 14155", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 42}, {"groupId": "EG001", "numAffected": 34, "numAtRisk": 41}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Latifa Foudali", "organization": "Medtronic", "email": "latifa.foudali@medtronic.com", "phone": "+33 631992144"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}